Replimune Group Inc (REPL) saw its stock soar 5.20% in Tuesday's pre-market trading session following a series of positive analyst actions. The biotechnology company received multiple upgrades and price target increases from prominent Wall Street firms, signaling growing confidence in its prospects.

JP Morgan raised its rating on Replimune from Underweight to Neutral, indicating a more favorable outlook on the company. Simultaneously, Piper Sandler upgraded the stock to Overweight from Neutral and significantly boosted its price target to $13 from $8, suggesting substantial upside potential. Jefferies also expressed optimism by raising its price target for Replimune to $13 from $8.

These upgrades and target price hikes reflect a growing positive sentiment among analysts regarding Replimune's business outlook and potential. While specific reasons for the improved outlook were not detailed in the available news, such actions often follow positive developments in a company's pipeline, financial performance, or market positioning. Investors responded enthusiastically to these analyst actions, driving the stock's pre-market surge.